Wuhan Hiteck Biological Pharma Co Ltd Market Cap ($426.18 Million)
Market Cap & Net Worth: Wuhan Hiteck Biological Pharma Co Ltd (300683)
Wuhan Hiteck Biological Pharma Co Ltd market cap. Wuhan Hiteck Biological Pharma Co Ltd (SHE:300683) has a market capitalization of $426.18 Million (CN¥2.91 Billion) as of November 6, 2026. Listed on the SHE stock exchange, this China-based company holds position #12774 globally and #3718 in its home market, demonstrating a 2.25% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Wuhan Hiteck Biological Pharma Co Ltd's stock price CN¥22.25 by its total outstanding shares 130894391 (130.89 Million). Also see 300683 cash flow conversion for how efficiently the company converts equity into cash flow.
Wuhan Hiteck Biological Pharma Co Ltd Market Cap History (2017–2026)
Wuhan Hiteck Biological Pharma Co Ltd market cap history from 2017 to 2026. Data shows change from $1.03 Billion to $426.18 Million (-7.69% CAGR). Check 300683 live share price for real-time trading data and today's change.
Wuhan Hiteck Biological Pharma Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Wuhan Hiteck Biological Pharma Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Wuhan Hiteck Biological Pharma Co Ltd to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.98x
Wuhan Hiteck Biological Pharma Co Ltd's market cap is 0.98 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $1.03 Billion | $750.26 Million | $142.39 Million | 1.37x | 7.22x |
| 2018 | $516.80 Million | $590.87 Million | $94.14 Million | 0.87x | 5.49x |
| 2019 | $574.64 Million | $620.16 Million | $63.04 Million | 0.93x | 9.12x |
| 2020 | $783.01 Million | $524.12 Million | -$25.03 Million | 1.49x | N/A |
| 2021 | $1.14 Billion | $614.68 Million | $27.65 Million | 1.86x | 41.25x |
| 2022 | $678.05 Million | $688.63 Million | -$14.03 Million | 0.98x | N/A |
| 2023 | $691.65 Million | $602.28 Million | -$120.82 Million | 1.15x | N/A |
| 2024 | $456.63 Million | $648.97 Million | -$69.35 Million | 0.70x | N/A |
| 2025 | $531.14 Million | $541.45 Million | -$231.27 Million | 0.98x | N/A |
Competitor Companies of 300683 by Market Capitalization
Companies near Wuhan Hiteck Biological Pharma Co Ltd in the global market cap rankings as of November 6, 2026. Also see 300683 current and non-current assets for a full breakdown of the balance sheet.
Key companies related to Wuhan Hiteck Biological Pharma Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Wuhan Hiteck Biological Pharma Co Ltd (2017–2026)
Market capitalization of Wuhan Hiteck Biological Pharma Co Ltd from 2017 to today. Between 2017 and today, Wuhan Hiteck Biological Pharma Co Ltd's market cap moved from $1.03 Billion to $ 426.18 Million, with a yearly change of -7.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥426.18 Million | -19.76% |
| 2025 | CN¥531.14 Million | +16.32% |
| 2024 | CN¥456.63 Million | -33.98% |
| 2023 | CN¥691.65 Million | +2.01% |
| 2022 | CN¥678.05 Million | -40.56% |
| 2021 | CN¥1.14 Billion | +45.69% |
| 2020 | CN¥783.01 Million | +36.26% |
| 2019 | CN¥574.64 Million | +11.19% |
| 2018 | CN¥516.80 Million | -49.75% |
| 2017 | CN¥1.03 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Wuhan Hiteck Biological Pharma Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $426.18 Million USD |
| MoneyControl | $426.18 Million USD |
| MarketWatch | $426.18 Million USD |
| marketcap.company | $426.18 Million USD |
| Reuters | $426.18 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Wuhan Hiteck Biological Pharma Co Ltd
Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the production and sales of bioengineering products and lyophilized powder injections in China and internationally. The company operates through Biopharmaceutical Division; Pharmaceutical Technology Services Division; In Vitro Diagnostic Reagents Division; Production and Sales Division of Active Pharmaceutical Ingredi… Read more